Dr. Bryan Mehlhaff on PSA's Role in Prostate Cancer

Bryan Mehlhaff, MD
Published: Monday, Nov 28, 2016


Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses the controversy surrounding prostate-specific antigen (PSA) testing in prostate cancer.
 
The United States Preventative Services Task Force gave PSA testing a grade ‘D’ recommendation in 2012 based on evidence regarding both the benefits and harms of the service and an assessment of the balance.
 
Since the D grade was announced a lot less screening has been conducted, says Mehlhaff, especially in men in their 50s or 60s. Mehlhaff believes this has lead to delayed diagnosis of prostate cancers and more men being diagnosed with advanced stage, hormone-sensitive prostate cancer.

Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses the controversy surrounding prostate-specific antigen (PSA) testing in prostate cancer.
 
The United States Preventative Services Task Force gave PSA testing a grade ‘D’ recommendation in 2012 based on evidence regarding both the benefits and harms of the service and an assessment of the balance.
 
Since the D grade was announced a lot less screening has been conducted, says Mehlhaff, especially in men in their 50s or 60s. Mehlhaff believes this has lead to delayed diagnosis of prostate cancers and more men being diagnosed with advanced stage, hormone-sensitive prostate cancer.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x